Lexaria Bioscience (LEXX) announces that ethics approval has been received from an independent review board, for Human Pilot Study #7 that will evaluate two oral DehydraTECH-semaglutide compositions against Novo Nordisk’s (NVO) commercially available Wegovy tablets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience provides update on Human Pilot Study #7
- Lexaria Bioscience extends material transfer agreement with pharma company
- Lexaria Bioscience launches new study to examine next-gen GLP-1 drugs
- Lexaria Bioscience provides update on GLP-1 oral pill market
- Lexaria Launches New GLP-1 Study to Expand Drug Delivery IP